Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Active, not recruiting · NCT03891953 · Registry updated 2026-01-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, otorhinolaryngologic disease, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2026-01-21 | NCT03891953 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |